Last reviewed · How we verify
High dose Oliceridine
High dose Oliceridine is a Mu-opioid receptor agonist (biased agonist) Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently FDA-approved for Moderate to severe acute pain in adults.
Oliceridine is a mu-opioid receptor agonist that selectively activates G-protein signaling pathways to provide analgesia with potentially reduced beta-arrestin signaling.
Oliceridine is a mu-opioid receptor agonist that selectively activates G-protein signaling pathways to provide analgesia with potentially reduced beta-arrestin signaling. Used for Moderate to severe acute pain in adults.
At a glance
| Generic name | High dose Oliceridine |
|---|---|
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Drug class | Mu-opioid receptor agonist (biased agonist) |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oliceridine binds to mu-opioid receptors and preferentially activates G-protein coupled signaling over beta-arrestin pathways, which may reduce some opioid-related adverse effects compared to traditional mu-opioid agonists. This biased signaling approach aims to maintain analgesic efficacy while potentially decreasing respiratory depression, constipation, and other side effects associated with conventional opioids.
Approved indications
- Moderate to severe acute pain in adults
Common side effects
- Nausea
- Dizziness
- Vomiting
- Headache
- Respiratory depression
Key clinical trials
- Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery (PHASE4)
- Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study (NA)
- 1.Comparison of the Analgesic Effect of Remifentanil Group and Different Dose Groups of Oliceridine in Postoperative Patients Undergoing Cardiac Surgery 2.Exploring the Hemodynamic Effects of Analgesic Regimens With Different Doses of Oliceridine After Cardiac Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose Oliceridine CI brief — competitive landscape report
- High dose Oliceridine updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI
Frequently asked questions about High dose Oliceridine
What is High dose Oliceridine?
How does High dose Oliceridine work?
What is High dose Oliceridine used for?
Who makes High dose Oliceridine?
What drug class is High dose Oliceridine in?
What development phase is High dose Oliceridine in?
What are the side effects of High dose Oliceridine?
What does High dose Oliceridine target?
Related
- Drug class: All Mu-opioid receptor agonist (biased agonist) drugs
- Target: All drugs targeting Mu-opioid receptor (OPRM1)
- Manufacturer: Nanjing First Hospital, Nanjing Medical University — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe acute pain in adults
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing